Table 3.
Characteristics of patients with pancreatic ductal adenocarcinoma who underwent circulating tumor DNA (ct‐DNA) monitoring
| Total | KRAS G12/13 mutated cases | NRAS‐mutated case | ||||
|---|---|---|---|---|---|---|
| Not detected in ct‐DNA at time of diagnosis | Detected in ct‐DNA at the time of diagnosis | |||||
| Total | Disappeared | Remained | ||||
| N | 21 | 7 | 13 | 8 | 5 | 1 |
| Gender; female, male | 7, 14 | 3, 4 | 3, 10 | 3, 5 | 0, 5 | 1, 0 |
| Age, years; average (range) |
64 (27‐78) |
67 (57‐74) |
65 (42‐78) |
64 (42‐77) |
67 (57‐78) |
27 (27) |
| Stage (UICC 7th) |
1, 7, 13 (ⅡB, Ⅲ, Ⅳ) |
1, 5, 1 (ⅡB, Ⅲ, Ⅳ) |
2, 11 (Ⅲ, Ⅳ) |
2, 6 (Ⅲ, Ⅳ) |
5 (Ⅳ) |
1 (Ⅳ) |
| KRAS G12/13 mutation in tissue DNA | Yes, 20 | Yes, 7 | Yes, 13 | Yes, 8 | Yes, 5 | Yes, 0 |
| No, 1 | No, 0 | No, 0 | No, 0 | No, 0 | No, 1 | |
| (NRAS Q61R detected) | (NRAS Q61R detected) | |||||
|
MAF in ct‐DNA (%) at the time of diagnosis (KRAS or NRAS), average ± SD |
2.8 ± 7.1 | 0.0 ± 0.0 | 2.2 ± 3.9 | 3.1 ± 4.7 | 0.9 ± 1.2 | 31.2 ± 0.0 |
| 1st regimen | GN, 18 | GN, 5 | GN, 12 | GN, 8 | GN, 4 | GN, 1 |
| mFFX, 1 | mFFX, 1 | GEM, 1 | GEM, 1 | |||
| GEM, 1 | S1, 1 | |||||
| S1, 1 | ||||||
| CEA, ng/mL; average ± SD | 42.7 ± 136.4 | 6.0 ± 4.0 | 65.7 ± 169.3 | 21.7 ± 20.4 | 55 476.0 ± 128 563.7 | 1.8 ± 0.0 |
| CEA > 5 ng/mL | 15 | 4 | 11 | 7 | 4 | 0 |
|
CA19‐9 (U/mL) Ave. ± SD |
22 165.8 ± 63 597.2 | 2330.1 ± 4968.2 | 34 550.6 ± 104 272.8 | 136.0 ± 256.5 | 1070.0 ± 1409.6 | 12.0 ± 0.0 |
| CA19‐9 > 37 U/mL | 17 | 6 | 11 | 7 | 4 | 0 |
Abbreviations: CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; GEM, gemcitabine; GN, gemcitabine plus nab‐paclitaxel; MAF, mutation allele frequency; mFFX, modified FOLFIRINOX; S1, tegafur (masked compound of 5‐fluorouracil).